This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund the expansion of the Youth Opioid Recovery Support (YORS) intervention for adolescents with opioid use disorder (OUD). The $1,153,350 award, spanning September 2024 to August 2027, aims to enhance medication adherence and reduce opioid relapse among this critical but underserved population. Key project activities include: Testing the...
This federal Project Grant award of $844,475, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to test a bundled intervention to increase treatment uptake for patients with opioid use disorder (OUD) after emergency department (ED) discharge. The project will enroll 30 patients with OUD and nonfatal opioid overdoses in the R61 phase to assess the feasibility and acceptability of the bundled intervention, which...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $994,004 to Boston Medical Center Corporation (BMC) to engage adolescents, young adults, families, youth providers, pharmacists, and people who use drugs to explore perceptions of overdose risk and generate insights to guide future intervention development. The key objectives are to: 1) Explore overdose risk perceptions and safety precautions among...
This $1,717,104 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund a 3-year community-engaged effort to adapt, produce, and pilot test a written "Youth Overdose Prevention Toolkit" for use by clinicians in pediatric healthcare settings. The toolkit will provide practical, developmentally appropriate guidance on delivering evidence-based interventions including naloxone, drug testing strips,...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $385,000.00 to Loyola University of Chicago's Health Sciences Campus to conduct research on integrated treatment approaches for co-occurring opioid use disorder (OUD) and alcohol use disorder (AUD). The key objectives of this 3-year research project are to: 1) assess the effectiveness of integrated treatment regimens, including first-line...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is intended to develop and evaluate a brief, digitally-enhanced intervention called IMPROVE to reduce alcohol use among individuals receiving medication for opioid use disorder (MOUD). The $630,000 award will be used to adapt the IMPROVE intervention, which targets anxiety sensitivity and intolerance of uncertainty, and conduct a pilot randomized controlled...
This $360,720 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support a randomized controlled trial examining the use of extended-release injectable buprenorphine in adults with opioid use disorder (OUD) who use high-potency synthetic opioids. The key objectives are to: 1) compare abstinence and relapse rates between injectable buprenorphine and sublingual buprenorphine/naloxone during a 2-day inpatient...
The National Institute on Drug Abuse (NIDA) awarded a $3,503,736 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Seattle Children's Hospital to develop and test a multilevel substance use disorder (SUD) and overdose prevention strategy for youth involved in rural county legal systems. The 2-year R61 phase will co-design the multilevel SUD/overdose prevention strategy and implementation plan with input from state/local governments, service providers, and...
This $1,594,478 federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support a 5-year prospective, observational study of 300 participants initiating treatment with medications for opioid use disorder (MOUD). The key objectives are to: 1) curate a dataset of craving patterns during MOUD using continuous wearable sensor data; 2) model craving trajectories and examine factors associated with opioid use...
This $197,748 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to develop and pilot an enhanced low-dose buprenorphine initiation (LDI) program to improve treatment outcomes for individuals with opioid use disorder (OUD), particularly those using fentanyl. The key objectives are to: 1) identify barriers to LDI completion through patient, clinician, and system leader interviews; 2) design an enhanced LDI...
THE YOUTH OPIOID RECOVERY SUPPORT (YORS) INTERVENTION: AN ASSERTIVE COMMUNITY TREATMENT MODEL FOR IMPROVING MEDICATION ADHERENCE IN YOUNG ADULTS WITH OPIOID USE DISORDER - PROJECT SUMMARY/ABSTRACT: YOUNG PEOPLE ARE DISPROPORTIONATELY AFFECTED BY THE CURRENT OPIOID CRISIS INCLUDING WORSE RETENTION AND OUTCOMES COMPARED TO OLDER ADULTS. FURTHER, YOUNG ADULTS TYPICALLY DO NOT HAVE ACCESS TO MEDICATIONS FOR OPIOID USE DISORDER (OUD), AND FOR THOSE THAT DO, STRUGGLES WITH ADHERENCE ARE A MAJOR BARRIER. STANDARD APPROACHES TO TREATMENT TYPICALLY DO NOT INCORPORATE DEVELOPMENTALLY INFORMED STRATEGIES FOR ENGAGEMENT, RETENTION, AND MEDICATION ADHERENCE FOR THIS SPECIAL POPULATION. THE YOUTH OPIOID RECOVERY SUPPORT (YORS) MODEL IS AN INNOVATIVE WRAP-AROUND APPROACH THAT ATTEMPTS TO ADDRESS BARRIERS TO TREATMENT ENGAGEMENT IN THIS VULNERABLE YOUNG ADULT POPULATION, ESPECIALLY DIFFICULTIES WITH MEDICATION ADHERENCE. ITS COMPONENTS INCLUDE: (1) HOME DELIVERY OF EXTENDED RELEASE NALTREXONE (XR- NTX) FOR OUD; (2) ENGAGEMENT OF FAMILIES IN COLLABORATIVE TREATMENT PLANNING AND MONITORING FOCUSING ON MEDICATION ADHERENCE; (3) ASSERTIVE OUTREACH FROM THE TREATMENT TEAM INCLUDING ACTIVELY TRACKING AND COMMUNICATING WITH YOUTH AND FAMILIES BY TEXT MESSAGING AND SOCIAL MEDIA TO PROMOTE ENGAGEMENT AND ADHERENCE; AND (4) CONTINGENCY MANAGEMENT TO PROVIDE INCENTIVES FOR MEDICATION ADHERENCE. YORS IS CURRENTLY SHOWING VERY PROMISING RESULTS IN A SMALL PILOT RCT BY THE INVESTIGATIVE TEAM. WE PROPOSE TO REFINE AND THEN CONDUCT A MORE DEFINITIVE TEST OF THE YORS INTERVENTION FOR YOUTH WITH OUD USING THE R61/R33 MECHANISM. IN THE R61 PHASE WE WILL CONDUCT STAKEHOLDER FOCUS GROUPS TO GET INPUT AND FEEDBACK ON POTENTIAL REFINEMENTS, WHILE ALSO CONDUCTING 3 CYCLES OF PILOT TESTING OF THESE POTENTIAL REFINEMENTS. BASED ON THE R61 PREPARATION AND FINAL SYNTHESIS OF THE INTERVENTION REFINEMENTS, IN THE R33 PHASE WE WILL CONDUCT AN RCT TO TEST THE EFFICACY OF YORS, BY RANDOMIZING N=120 YOUNG ADULTS AGES 18-26 SEEKING TREATMENT FOR OUD WITH XR-NTX AT MOUNTAIN MANOR TREATMENT CENTER (MMTC), TO EITHER THE REFINED YORS INTERVENTION OR TREATMENT AS USUAL (TAU) FOR A 6-MONTH COURSE OF TREATMENT WITH XR-NTX. THE PRIMARY OUTCOME WILL BE NUMBER OF XR-NTX DOSES RECEIVED. SECONDARY OUTCOMES WILL INCLUDE OPIOID RELAPSE, DAYS OF OPIOID USE, TIME TO FIRST OPIOID RELAPSE, HIV RISK BEHAVIORS, CRIMINAL BEHAVIORS, PSYCHIATRIC SYMPTOMS, AND FAMILY MEMBER DISTRESS AND SELF-EFFICACY. IT IS HYPOTHESIZED THAT PARTICIPANTS IN THE YORS CONDITION WILL RECEIVE SIGNIFICANTLY MORE XR-NTX DOSES AND WILL DEMONSTRATE LESS SEVERE OPIOID USE AND ASSOCIATED BEHAVIORS COMPARED TO THOSE IN THE TAU GROUP. THE ASSERTIVE YORS INTERVENTION HAS THE POTENTIAL TO IMPROVE THE REAL-WORLD EFFECTIVENESS AND PUBLIC HEALTH IMPACT OF MEDICATION FOR OUD IN THIS VERY HIGH-RISK, VULNERABLE POPULATION. IF THE REFINED YORS INTERVENTION IS FOUND TO BE EFFICACIOUS, IT WOULD SET THE STAGE FOR FUTURE WORK INCLUDING: AN ECONOMIC ANALYSIS, A LARGER MULTI-SITE STUDY, LONGER INTERVENTION DURATION, STUDY OF EXTENDED RELEASE BUPRENORPHINE, AND STUDY OF STEP-DOWN TO LESS INTENSIVE INTERVENTIONS.